#1 Clinical Trials Search in Europe

Syn2

SYN2 is an innovative 18F-labelled tracer being studied in clinical trials for its potential in diagnosing coronary artery disease (CAD). These trials aim to evaluate the effectiveness of SYN2 in Positron Emission Tomography (PET) imaging for patients with suspected heart conditions. The studies focus on assessing the diagnostic performance, safety, and ability to quantify myocardial blood flow using SYN2 PET imaging.

Table of Contents

What is SYN2?

SYN2 is a novel diagnostic tool being developed to help detect coronary artery disease (CAD). It is a solution for injection that contains a special substance labeled with a radioactive element (18F)[1]. This innovative tracer is designed to be used in a medical imaging technique called Positron Emission Tomography (PET), which can create detailed pictures of the heart.

Medical Condition: Coronary Artery Disease

Coronary artery disease is a condition where the blood vessels that supply the heart with oxygen and nutrients become narrowed or blocked. This can lead to chest pain, shortness of breath, or even heart attacks. Early and accurate diagnosis of CAD is crucial for proper treatment and management of the condition[1][2].

How SYN2 Works

SYN2 is used in a procedure called PET Myocardial Perfusion Imaging (PET MPI). Here’s how it works:

  1. The SYN2 solution is injected into the patient’s bloodstream.
  2. The radioactive tracer travels to the heart.
  3. A PET scanner takes pictures of the heart, showing how blood flows through the coronary arteries and into the heart muscle.
  4. Doctors analyze these images to detect areas of reduced blood flow, which may indicate coronary artery disease.

This method allows for quantitative analysis of blood flow in the heart, which means doctors can measure exactly how much blood is flowing through different parts of the heart muscle[2].

Clinical Trials

SYN2 is currently being studied in clinical trials to evaluate its effectiveness in diagnosing coronary artery disease. Two main studies are underway:

  • Phase III Multicenter Study: This study aims to assess how well SYN2 PET MPI can detect significant coronary artery disease compared to standard diagnostic methods[1].
  • Myocardial Blood Flow Quantification Study: This study focuses on validating SYN2’s ability to accurately measure blood flow in the heart muscle. It compares SYN2 to another established PET tracer called 13N-ammonia[2].

These studies will help determine how accurate and reliable SYN2 is in diagnosing coronary artery disease and measuring heart blood flow.

Eligibility Criteria

To participate in the SYN2 clinical trials, patients must meet certain criteria. Some key points include:

  • Being over 18 years of age
  • Having suspected coronary artery disease
  • Being able to undergo stress testing (either through exercise or medication)
  • Not having certain heart conditions like severe heart failure or previous heart transplants
  • For women of childbearing potential, using effective contraception

It’s important to note that these are general criteria, and each study may have specific requirements. Always consult with your doctor or the study team for detailed information[1][2].

Safety Considerations

As with any medical procedure, there are some safety considerations to keep in mind:

  • SYN2 is still being studied, so all potential side effects may not be known yet.
  • Patients with known allergies to SYN2 components or similar substances should not use this tracer.
  • Pregnant or breastfeeding women are not eligible for these studies due to the use of radioactive materials.
  • The studies monitor for any adverse events or side effects to ensure patient safety.

It’s crucial to discuss any concerns or questions about safety with your healthcare provider or the study team[1][2].

Aspect Details
Drug Name SYN2
Type 18F-labelled tracer
Purpose Diagnosis of Coronary Artery Disease (CAD)
Imaging Method Positron Emission Tomography (PET)
Main Objectives 1. Evaluate diagnostic performance in detecting CAD
2. Enable quantitative myocardial blood flow assessment
Key Inclusion Criteria 1. Adults over 18 years
2. Suspected CAD
3. Capable of stress imaging protocols
Key Exclusion Criteria 1. Established CAD diagnosis
2. Severe heart conditions
3. Pregnancy
Safety Monitoring Adverse events, laboratory parameters, ECG, physical examination

FAQ

  • What is SYN2 and how is it used in clinical trials? SYN2 is a novel 18F-labelled tracer used in Positron Emission Tomography (PET) imaging. In clinical trials, it's being studied to assess its effectiveness in diagnosing coronary artery disease (CAD) in patients with suspected heart conditions.
  • What is the main objective of the SYN2 clinical trials? The main objectives are to evaluate the diagnostic performance of SYN2 PET imaging in detecting significant coronary artery disease and to enable and validate quantitative myocardial blood flow assessment using SYN2.
  • Who can participate in these clinical trials? Generally, participants must be over 18 years old, have suspected coronary artery disease, be capable of undergoing stress imaging protocols, and meet other specific inclusion criteria. People with established CAD, severe heart conditions, or pregnancy are typically excluded.
  • What procedures are involved in the SYN2 clinical trials? The trials involve PET imaging using SYN2, sometimes compared with 13N-ammonia PET studies. Participants may undergo pharmacological or exercise stress tests as part of the imaging procedures.
  • Are there any safety concerns with SYN2? The trials are monitoring for adverse events and serious adverse reactions. Participants with known allergies to SYN2 components or similar substances are excluded. As with any clinical trial, safety is a key focus of the study.

Ongoing Clinical Trials on Syn2

  • Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions

    Recruiting

    3 1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland Germany Italy The Netherlands Poland

  • Study on Coronary Artery Disease: Evaluating Myocardial Blood Flow Using SYN2, Regadenoson, and Adenosine in Patients with Heart Conditions

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Coronary Artery Disease (CAD): A condition where the blood vessels supplying the heart become narrowed or blocked, often due to plaque buildup.
  • Positron Emission Tomography (PET): An imaging technique that uses a small amount of radioactive material to reveal how tissues and organs are functioning.
  • Myocardial Blood Flow: The blood supply to the heart muscle, which is crucial for its proper functioning.
  • Tracer: A substance used in medical imaging to help visualize specific parts of the body or bodily functions.
  • Pharmacological Stress Test: A procedure that uses medication to simulate the effects of exercise on the heart, used when a patient can't exercise during a stress test.
  • Invasive Coronary Angiography (ICA): A procedure that uses X-rays and a special dye to see inside the heart's blood vessels.
  • Myocardial Perfusion Imaging (MPI): A non-invasive imaging test that shows how well blood flows through the heart muscle.
  • Quantitative Analysis: A method of examining data using mathematical and statistical modeling to derive precise measurements.
  • Stenosis: The abnormal narrowing of a blood vessel, which can restrict blood flow.
  • Revascularization: A procedure to restore blood flow to a body part or organ, often referring to treatments for blocked arteries in the heart.

References

  1. http://clinicaltrials.eu/trial/study-on-the-use-of-syn2-adenosine-and-regadenoson-for-diagnosing-coronary-artery-disease-in-patients-with-suspected-heart-conditions/
  2. http://clinicaltrials.eu/trial/study-on-coronary-artery-disease-evaluating-myocardial-blood-flow-using-syn2-regadenoson-and-adenosine-in-patients-with-heart-conditions/